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Introduction: Disease activity and therapy show an impact on cellular and serological parameters in patients with
systemic lupus erythematosus (SLE). This study was performed to compare the influence of mycophenolate mofetil
(MMF) and cyclophosphamide (CYC) therapy on these parameters in patients with flaring, organ-threatening disease.
Methods: SLE patients currently receiving CYC (n = 20), MMF (n = 25) or no immunosuppressive drugs (n = 22)
were compared using a cross-sectional design. Median disease activity and daily corticosteroid dose were similar
in these treatment groups. Concurrent medication, organ manifestations, and disease activity were recorded, and
cellular and serological parameters were determined by routine diagnostic tests or flow cytometric analysis. In
addition follow-up data were obtained from different sets of patients (CYC n = 24; MMF n = 23).
Results: Although both drugs showed a significant effect on disease activity and circulating B cell subsets, only
MMF reduced circulating plasmablasts and plasma cells as well as circulating free light chains within three months
of induction therapy. Neither MMF nor CYC were able to reduce circulating memory B cells. MMF lowered IgA
levels more markedly than CYC. We did not observe a significant difference in the reduction of IgG levels or
anti-dsDNA antibodies comparing patients receiving MMF or CYC. In contrast to MMF, induction therapy with
CYC was associated with a significant increase of circulating CD8+ effector T cells and plasmacytoid dendritic cells
(PDCs) after three months.
Conclusions: The results indicate differences between MMF and CYC with regard to the mechanism of action.
MMF, but not CYC, treatment leads to a fast and enduring reduction of surrogate markers of B cell activation, such
as circulating plasmablasts, plasma cells and free light chains but a comparable rate of hypogammaglobulinemia.Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease associated with significant morbidity
and mortality. SLE is a heterogeneous disease involving
hematologic, neurologic, dermatologic, musculoskeletal
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stated.affected by SLE (female:male ratio of 6:1 to 10:1) requir-
ing treatment with immunosuppressive drugs and other
medications [1,2]. Treatment guidelines based on clin-
ical trials have been published recently [3-5]. However,
due to the heterogeneity of the disease, employment of
immunosuppressive drugs is largely based on clinical ex-
perience [6]. Besides hydroxychloroquine and prednisone,
antiproliferative or cytotoxic reagents, such as azathio-
prine (AZA), methotrexate (MTX), mycophenolate mofe-
til (MMF) or cyclophosphamide (CYC), are used to treat
SLE. These drugs are able to reduce morbidity andtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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lapse of the disease.
The pathogenesis of SLE is complex. A loss of toler-
ance to self-antigens as well as a dysregulated T and B
cell activation are implicated in the pathogenesis of SLE
[7]. In particular, activation of B cells and the loss of B
cell tolerance play a pivotal role in SLE, because B cells
present antigens, produce numerous autoantibodies and
proinflammatory cytokines and activate T cells [8]. In this
context, alterations of circulating lymphocyte and den-
dritic cell subsets have been observed, such as plasma cells
[9], transitional B cells [10], pre-switched memory B cells
[11,12], regulatory T cells [13], CD4−CD8− T cells [14] or
plasmacytoid dendritic cells (PDC) [15]. However, it is not
clear, if these abnormalities are related to disease activity,
therapeutic interventions, or both. By comparing patients
receiving maintenance therapy with AZA or MMF using a
cross-sectional design, we observed that different drugs
used for the same purpose target distinct cell subsets, as
for instance MMF blocks plasma cell differentiation
whereas AZA reduces naïve and transitional B cells
[16,17]. However, our knowledge about the mechanism
of action of many drugs used to treat lupus is still lim-
ited. Therefore, we continued to investigate the effects
of immunosuppressive drugs used to induce or maintain
remission in patients with SLE.
Methods
Patients
All data were obtained from patients fulfilling the American
College of Rheumatology (ACR) criteria for the classifica-
tion of SLE [18,19] attending the Division of Rheumatology
and Clinical Immunology of the Department of Internal
Medicine D at Münster University Hospital. Patients gave
written informed consent to a retrospective analysis of all
data acquired during their routine visits. Ethical approval
for retrospective analysis of serological, clinical and cel-
lular data obtained to assess disease activity or safety of
treatment was waived by the ‘Ethik-Kommission der
Ärztekammer Westfalen-Lippe und der Medizinischen
Fakultät der Westfälischen Wilhelms Universität Münster’.
Patients included in the analysis had to be on their medi-
cation for at least ten weeks.
For a cross-sectional analysis, cellular, serological, and
clinical parameters were recorded in patients receiving
immunosuppressive therapy with MMF (n = 25) or CYC
(n = 20). The following primary features, that is, nephritis
(n = 18), mucocutaneous (n = 3); arthritis (n = 3) or myo-
sitis (n = 1) in the MMF group and nephritis (n = 17),
myositis (n = 2) or alveolitis (n = 1) in the CYC group led
to the respective therapy. In addition, all manifestations
still active at the time point of analysis are given in Table 1.
Since it is known that corticosteroid intake and disease ac-
tivity influence cellular and serological parameters, patientgroups showing similar median disease activity or daily
corticosteroid dose were compared as shown in Table 1.
Patients treated with MMF had been receiving a daily dose
of 1,000 mg (n = 2), 1,500 mg (n = 7), 2,000 mg (n = 12),
2,500 mg (n = 1) or 3,000 mg (n = 3) MMF for ten weeks
to six month (n = 4), six to twelve months (n = 2) or more
than one year (n = 19) prior to analysis. All patients in the
CYC group received intravenous (i.v.) pulses. Of these, the
majority (n = 15) was analyzed after CYC treatment ac-
cording to the Euro-Lupus Trial protocol [20]. They re-
ceived 0.5 g CYC every two weeks for a total of twelve
weeks. The remaining five patients received i.v. CYC once
every four weeks for four to twelve months. For compari-
son another group of lupus patients (n = 22) with similar
disease activity and daily corticosteroid use was identified
and parameters of these patients were recorded prior to
increasing treatment intensity (controls). The clinical and
demographic data as well as medication and serological
parameters of these patients are shown in Table 1.
For the follow-up analysis we identified 47 flaring pa-
tients requiring treatment with CYC (n = 24) or MMF
(n = 23) because of severe flares of nephritis (n = 18),
myositis (n = 2), neuropsychiatric manifestations (n = 3)
or alveolitis (n = 1) in the CYC treated group and neph-
ritis (n = 17), arthritis (n = 3), myositis (n = 1), vasculitis
(n = 1) or neuropsychiatric manifestations (n = 1) in the
MMF treated group. In addition, all manifestations ac-
tive prior to treatment are given in Table 2. All subjects
were investigated prior to treatment and after 15 (range:
10 to 39) weeks of i.v. CYC application (in 17 of 24 cases
according to the Euro-Lupus Trial protocol [20] or 16 (10
to 65) weeks after starting MMF. Patients taking MMF re-
ceived a daily dose of 1,500 mg (n = 3), 2,000 mg (n = 16)
or 3,000 mg (n = 4) MMF. Again, both treatment groups
showed a similar median disease activity and daily cortico-
steroid dose.
Data of 20 patients were analyzed repeatedly approxi-
mately 31 (18 to 111) weeks after starting MMF treatment.
Since the major percentage of the patients receiving CYC
was treated according to the Euro-Lupus Trial protocol
[20] no further follow-up parameters could be collected
for this group. Clinical, serological, demographic data
and the preceding immunosuppressive medication are
given in Table 2.
Furthermore, plasmablasts, plasma cells and immuno-
globulin (Ig)-, as well as free light chain levels, were
determined in 186 lupus patients and data were analyzed
using Spearman’s rank correlation test. The mean age of
these patients was 38.2 ± 12.3 years ranging from 18 to
72 years. Of these patients, 81.7% were female, 30.0%
received MMF, 21.5% AZA, 9.7% MTX, 12.4% CYC, and
28.5% no immunosuppressive medication except steroids
and antimalarials. The median SLEDAI-2 k of these 186
patients was 6 (0 to 24).
Table 1 Demographic, serological, clinical data and medication of patients treated with MMF or CYC compared to
controls
Demographic, serological,
clinical data and medication
MMF CYC Controls
(number = 25) (number = 20) (number = 22)
SLEDAI-2 k (points); median (range) 8 (2 to 14) 11 (0 to 16) 9 (3 to 18)
gender female number (%) 18 (72.0) 14 (70.0) 18 (81.8)
age (years); mean ± SD 38 ± 13 34 ± 9 40 ± 14
duration (years); median (range) 9 (2 to 28)a 4 (0 to 25)a 10 (0 to 26)
age at initial diagnosis of SLE (years); mean ± SD 27 ± 11 29 ± 10 29 ± 14
medication
prednisone (mg/day); median (range) 7.0 (2.5 to 15.0) 10.0 (0.0 to 30.0) 6.3 (0.0 to 100.0)
co-medication with antimalarials number (%) 18 (72.0) 12 (60.0) 16 (72.7)
currently active manifestations number (%)
class III-V nephritis 10 (40.0) 12 (60.0) 6 (27.3)
eGFR <60 ml/min 7 (28.0) 4 (20.0) 3 (13.6)
C3c <0.9 g/L 18 (72.0) 14 (70.0) 16 (72.7)
neuropsychiatric 0 0 0
mucocutaneous/cutaneous 8 (32.0) 8 (40.0) 7 (31.8)
arthritis 5 (20.0) 0bb 9 (40.9)bb
serositis 1 (4.0) 0 4 (18.2)
myositis 1 (4.0) 1 (5.0) 1 (4.5)
autoantibodies number (%)
anti-dsDNA >7 U/ml 21 (84.0) 15 (75.0) 20 (90.9)
anti-Ro >7 U/ml 11 (44.0) 10 (50.0) 13 (59.1)
anti-La >7 U/ml 4 (16.0) 4 (20.0) 4 (18.2)
anti-U1-RNP >5 U/ml 11 (44.0) 12 (60.0) 8 (36.4)
anti-SM >5 U/ml 7 (28.0) 9 (45.0) 4 (18.2)
Statistically significant differences (Dunn’s multiple comparisons test or Fisher’s exact test) were observed between patients receiving MMF and CYC (a) and patients
receiving CYC versus controls (b) one (P <0.05), two (P <0.01) symbols ab. C3c: complement factor C3c, controls: patients with SLE not receiving MMF or CYC; CYC:
cyclophosphamide; eGFR: estimated glomerular filtration rate; MMF: mycophenolate mofetil; SLE: systemic lupus erythematosus; SLEDAI-2 k: SLE disease activity index.
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Routine laboratory analyses including differential blood
counts and complement factor C3c (turbidimetry), as well
as autoantibody (radioimmuno- or fluorescence-enzyme-
immunoassay), Ig levels (turbidimetry), and free light
chain concentrations (nephelometry) were measured in
the central laboratory of the University Hospital of
Münster, Germany using accredited diagnostic proce-
dures. To be considered positive autoantibody levels
had to be higher than 7 U/ml (anti-dsDNA, anti-Ro, anti-
La) or higher than 5 U/ml (anti-U1-RNP and anti-Sm).
Flow cytometric analysis of peripheral blood mono-
nuclear cells (PBMC) was performed as described previ-
ously [16]. Briefly, PBMC from 5 ml of heparinized
blood were isolated by density gradient centrifugation
using Ficoll-Paque™ Plus (GE Healthcare, Freiburg,
Germany), were washed in phosphate-buffered saline
(PBS)/0.5% bovine serum albumin (BSA) (Sigma-Aldrich,
Taufkirchen, Germany), and stained immediately with
fluorchrome labeled monoclonal antibodies to a panel ofdifferent surface antigens to discriminate PDC, B and T
cell subsets as shown in Additional file 1. All samples
were analyzed within six hours after acquisition to en-
sure viability of all cell subsets. To exclude dead cells
4,6-diamidino-2-phenylindole (DAPI, final concentra-
tion 220 nM) (Invitrogen, Darmstadt, Germany) was
used. A FACS Canto-II and FACS Diva Software (Becton
Dickinson, Heidelberg, Germany) were used for a 12-
parameter (8-color) flow cytometric analysis. One million
events were recorded for B cell or dendritic cell analysis,
and 100,000 events for T cell analysis. Results were
analyzed using FlowJo Software (Treestar). Lymphocyte
counts were recorded and absolute numbers were calcu-
lated using the frequencies of PDC, T and B cells based on
the lymphocyte gate and the numbers of lymphocytes
counted simultaneously in the central laboratory.
Statistical analysis
We performed an exploratory analysis of a set of serological
and cellular parameters obtained from patients receiving
Table 2 Demographic, serological, clinical data and
medication prior to induction therapy
Demographic, serological,
clinical data and medication
MMF CYC
(number = 23) (number = 24)
SLEDAI-2 k (points); median (range) 12 (6 to 20) 14 (2 to 30)
gender female number (%) 15 (65.2) 16 (66.7)
age (years); mean ± SD 35 ± 10 34 ± 10
duration (years); median (range) 4 (1 to 24) 3 (0 to 25)
age at initial diagnosis of SLE (years);
mean ± SD
29 ± 10 30 ± 10
medication
prednisone (mg/day); median (range) 10.0 (5.0-30.0) 10.0 (0.0-250.0)
co-medication with antimalarials
number (%)
15 (65.2) 11 (45.8)
preceding immunosuppressive
medication number (%)
- CYC 11 (47.8)
- MMF 6 (25.0)
- AZA 8 (24.8) 7 (29.2)
- MTX 2 (8.7) 2 (8.3)
- CsA 1 (4.3) 1 (4.2)
- none 1 (4.3)a 8 (33.3)a
manifestations number (%)
class III-V nephritis flare 17 (73.9) 18 (75.0)
eGFR <60 ml/min 4 (18.2) 6 (25.0)
C3c <0.9 g/L 14 (60.9)b 23 (95.8)b
neuropsychiatric 1 (4.3) 3 (12.5)
mucocutaneous/cutaneous 14 (60.9) 14 (58.3)
arthritis 8 (34.8) 6 (25.0)
serositis 2 (8.7) 5 (20.8)
myositis 2 (8.7) 3 (12.5)
autoantibodies number (%)
anti-dsDNA >7 U/ml 21 (91.3) 21 (87.5)
anti-Ro >7 U/ml 15 (65.2) 13 (54.2)
anti-La >7 U/ml 5 (21.7) 5 (20.8)
anti-U1-RNP >5 U/ml 11 (47.8) 13 (54.2)
anti-SM >5 U/ml 8 (34.8) 11 (45.8)
Statistically significant differences between patients undergoing induction
therapy with CYC and MMF (Fisher’s exact test): aP = 0.0226; bP = 0.0044.
AZA: azathioprine; C3c: complement factor C3c; CsA: cyclosporine A; CYC:
cyclophosphamide; eGFR: estimated glomerular filtration rate; MMF:
mycophenolate mofetil; MTX: methotrexate; SLE: systemic lupus
erythematosus; SLEDAI-2 k: SLE disease activity index.
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No adjustment for multiple tests was performed.
A cross-sectional analysis was performed and results
were confirmed and supplemented by data obtained by a
follow-up analysis. Changes of serological and cellular
parameters were recorded and compared between differ-
ent treatment groups.Data were analyzed using GraphPad Prism 6 (GraphPad
Software, Inc.). P-values <0.05 were considered to be sta-
tistically significant. Since most data did not show a nor-
mal distribution, median values with range were applied
with few exceptions. The Mann–Whitney test and the
Fisher’s exact test were used to compare parameters of
two independent unrelated patient groups, and the
Wilcoxon’s signed rank test for the follow-up analysis.
The Kruskal-Wallis test and the Dunn’s Multiple Com-
parison test were used if more than two patient groups
were compared. Spearman’s rank correlation test was
used for the correlation analysis.
Results
Cross-sectional analysis
Major impact of CYC or MMF was seen on B cells and
B cell subsets. Counts of plasmablasts and plasma cells
were significantly lower in patients receiving MMF com-
pared to patients receiving CYC (P <0.0001 for both,
plasmablasts and plasma cells) and compared to controls
(P <0.001 for plasmablasts only). Consistent with these
findings, serum levels of free light chains, IgG, IgA and
IgM were lower in MMF treated patients compared to
patients receiving CYC or to controls, but significant
differences could only be detected with regard to free
kappa light chains (P <0.01 compared to CYC and
P <0.05 compared to controls), free lambda light chains
(P <0.05 compared to controls), IgA (P <0.01 compared
to CYC and P <0.05 compared to controls), and IgG
(P <0.05 compared to controls). In contrast, treatment
with CYC was associated with significantly lower counts
of naïve B cells compared to MMF (P <0.05) and with
significantly lower counts of total B lymphocytes
(P <0.05), of pre-switched memory cells (P <0.01), and
of naïve B cells (P <0.0001) compared to controls. We
did not observe any significant differences in counts of
leukocytes or total lymphocytes in the peripheral blood
of patients treated with CYC or MMF compared to
controls, nor did we notice any significant differences in
T lymphocyte subsets or in counts of circulating PDC.
Serological parameters as well as cell subset data are
shown in Table 3.
Follow-up analysis of patients on induction therapy
Although we observed obvious differences with regard
to lymphocyte subsets and PDC in patients receiving
induction therapy with MMF or CYC, both patient
groups showed a comparably good response to treat-
ment. SLEDAI-2 k decreased in both treatment groups
(MMF: 12 (6 to 20) versus 9 (0 to 16), (P = 0.0051), and
CYC: 14 (2 to 30) versus 12 (0 to 18), (P = 0.0019).
In line with the cross-sectional data, CYC as well as
MMF therapy showed a predominant impact on B cell sub-
sets and plasma cells. However, we observed a completely
Table 3 Median (range) of serological parameters and cell subsets of patients treated with MMF or CYC compared to
controls
Madian (range) serological parameters
and cell subsets
MMF CYC Controls
(number = 25) (number = 20) (number = 22)
anti-dsDNA (U/ml) 38 (0 to 927) 38 (0 to 7536) 28 (0 to 963)
C3c (g/L) 0.8 (0.4 to 1.1) 0.8 (0.5 to 1.5) 0.8 (0.2 to 1.4)
FLCkappa (mg/L) 19.0 (9.6 to 52.0)
aab 34.9 (1.6 to 246.0)aa 26.7 (9.2 to 148.0)b
FLClambda (mg/L) 21.8 (10.0 to 47.8)
b 30.2 (4.1 to 153.0) 32.8 (12.9 to 99.3)b
IgG (g/L 10.5 (4.9 to 16.3)b 11.8 (3.8 to 28.8) 13.4 (5.9 to 24.2)b
IgA (g/L) 2.1 (0.2 to 5.7)aab 3.3 (1.1 to 6.7)aa 2.8 (0.9 to 7.4)b
IgM (g/L) 0.9 (0.3 to 5.5) 1.1 (0.3 to 2.6) 1.1 (0.3 to 7.4)
lymphocytes (/μl) 800 (220 to 2160) 790 (230 to 1910) 890 (190 to 2310)
leukocytes (/μl) 6010 (2640 to 11450) 5835 (2400 to 14008) 6195 (2160 to 10700)
platelets (× 103/μl) 259 (170 to 451)bb 238 (68 to 355) 211 (47 to 325)bb
CD19+ B lymphocytes (/μl) 55.6 (2.8 to 365.0) 31.2 (4.8 to 206.1)c 103.0 (14.7 to 277.4)c
- CD27++CD38++ (/μl) 0.8 (0.0 to 7.4)aaaabb 7.3 (0.1 to 90.9)aaaa 2.5 (0.7 to 61.4)bb
- HLADRhighCD27++CD38++ (/μl) 0.4 (0.0 to 4.3)aaaabbb 4.3 (0.1 to 58.6)aaaa 1.8 (0.5 to 55.1)bbb
- HLADRlowCD27++CD38++ (/μl) 0.3 (0.0 to 3.2)aaaa 2.1 (0.0 to 32.3)aaaa 1.0 (0.2 to 6.3)
- CD27+IgD− (/μl) 4.0 (1.1 to 168.1) 6.2 (0.9 to 47.2) 10.2 (3.8 to 52.6)
- CD27+IgD+ (/μl) 0.9 (0.1 to 9.0) 0.8 (0.2 to 4.1)cc 2.2 (0.4 to 7.7)cc
- CD27−IgD+CD38+ (/μl) 26.2 (0.2 to 232.9)a 3.2 (0.0 to 106.4)acccc 50.7 (2.5 to 118.3)cccc
- CD27−IgD− (/μl) 10.0 (0.9 to 28.8) 7.0 (1.0 to 38.5) 14.2 (1.7 to 108.5)
- CD27−IgD+CD38++ (/μl) 2.3 (0.0 to 59.1) 2.4 (0.1 to 82.5) 4.9 (0.2 to 48.6)
CD3+ T lymphocytes (/μl) 463.4 (79.9 to 1562.0) 469.1 (120.5 to 1263.0) 616.0 (92.7 to 1675.0)
CD4+ (/μl) 317.2 (72.7 to 1142.0) 254.9 (88.6 to 858.2) 445.7 (46.6 to 1307.0)
- CD44+CD62L− (/μl) 23.4 (2.2 to 178.6) 26.5 (5.4 to 126.8) 28.5 (5.2 to 334.5)
- CD45RA−CD45RO+ (/μl) 105.5 (15.4 to 514.9) 120.2 (24.8 to 506.7) 148.2 (22.9 to 754.8)
- CD45RA+CD45RO− (/μl) 144.5 (27.7 to 511.3) 119.6 (19.9 to 534.7) 114.9 (19.0 to 633.9)
CD8+ (/μl) 112.6 (2.0 to 538.0) 140.8 (17.2 to 334.6) 142.6 (20.9 to 618.0)
- CD44+CD62L− (/μl) 21.5 (0.3 to 363.8) 33.4 (4.9 to 227.8) 15.3 (2.8 to 541.4)
- CD45RA−CD45RO+ (/μl) 16.1 (0.3 to 332.2) 31.5 (5.3 to 142.9) 24.6 (4.7 to 357.8)
- CD45RA+CD45RO− (/μl) 77.1 (1.4 to 485.8) 80.6 (10.5 to 250.1) 86.1 (4.9 to 370.5)
CD4−CD8− (/μl) 28.0 (2.2 to 97.2) 23.1 (6.2 to 98.4) 22.1 (2.9 to 174.2)
- CD44+CD62L− (/μl) 5.7 (0.1 to 71.6) 6.8 (1.5 to 38.3) 6.3 (1.0 to 166.0)
- CD45RA−CD45RO+ (/μl) 9.2 (0.1 to 43.0) 8.5 (0.5 to 55.8) 10.9 (0.7 to 68.6)
- CD45RA+CD45RO− (/μl) 17.9 (0.7 to 70.2) 12.7 (5.0 to 44.6) 13.3 (1.7 to 160.2)
CD123+CD11c−HLA-DRhigh PDCs (/μl) 1.8 (0.4 to 8.5) 2.0 (0.4 to 6.2) 0.8 (0.1 to 20.6)
Statistically significant differences (Dunn’s multiple comparisons test) were observed between patients receiving MMF and CYC (a) or controls (b) and patients
receiving CYC versus controls (c) one (P <0.05), two (P <0.01), three (P <0.001), four (P <0.0001) symbols abc. C3c: complement factor C3c; CD4+ T cells; CD4−CD8−:
double negative T cells; CD8+ T cells; CD27++CD38++: plasmablasts and plasma cells; CD27+IgD+: pre-switched memory B cells; CD27+IgD−: post-switched memory
B cells; CD27−IgD+CD38+: naïve B cells; CD27−IgD+CD38++: transitional B cells; CD27−IgD−: double negative B cells; CD44+CD62L−: effector T cells; CD45RA+CD45RO−:
naïve T cells; CD45RA−CD45RO+: memory T cells; CD123+CD11c−HLA-DRhighPDCs: plasmacytoid dendritic cells; controls: patients with SLE not receiving MMF or CYC;
CYC: cyclophosphamide; FLC: free light chains; HLADRhighCD27++CD38++: plasmablasts; HLADRlowCD27++CD38++: plasma cells; Ig: immunoglobulin; MMF: mycophenolate
mofetil; SLE, systemic lupus erythematosus.
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immunosuppressants. In detail, patients receiving MMF
showed a fast depletion of plasmablasts (3.2 (0.2 to 23.3)
versus 0.3 (0.1 to 3.6)/μl; P <0.0001) and of plasma cells
(1.4 (0.1 to 4.5) versus 0.3 (0.0 to 1.3)/μl; P <0.0001;Figure 1). In the further course of treatment with MMF,
both cell subsets remained at a low level (plasmablasts
0.4 (0.0 to 2.8)/μl and plasma cells 0.3 (0.0 to 1.7)/μl).
Consistent with these findings levels of free kappa (33.4
(1.6 to 124.0) versus 22.9 (6.7 to 85.5) mg/L) and free
Figure 1 Influence of an induction therapy with mycophenolate mofetil (MMF) or cyclophosphamide (CYC) on plasmablast and plasma cell
counts. CD27++CD38++HLADRhigh plasmablast (A) and CD27++CD38++HLADRlow plasma cell counts (C) prior to and approximately 16 and 31
weeks after start of induction therapy with MMF. CD27++CD38++HLADRhigh plasmablast (B) and CD27++CD38++HLADRlow plasma cell counts
(D) prior to and approximately 15 weeks after start of induction therapy with CYC. Statistical analyses were performed using the Wilcoxon’s
matched pairs signed rank test and P-values <0.05 were considered significant.
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mg/L) light chains declined significantly (P = 0.0007 and
P = 0.0017, respectively), and remained at a low level in
the further course of treatment (FLC kappa 19.0 (8.0 to
74.9) mg/L, and FLC lambda 24.0 (9.6 to 76.4) mg/L),
whereas no significant decline of free light chain levels was
observed in CYC treated patients (Figure 2). In addition,
neither counts of plasmablasts nor counts of plasma cells
changed significantly after approximately 15 weeks of ther-
apy with CYC (Figure 1).
Levels of IgM decreased significantly in both treatment
groups (MMF: 1.1 (0.3 to 4.2) versus 0.9 (0.2 to 4.2) g/L;
P = 0.0125 and CYC: 1.1 (0.3 to 3.5) versus 1.1 (0.2 to
2.6) g/L; P = 0.0214). A statistically significant decline of
IgG (12.9 (5.6 to 47.0) versus 10.8 (3.8 to 28.8) g/L; P =
0.0250) was only seen in CYC treated patients, whereas
MMF treatment was significantly more effective than
CYC treatment in reducing the IgA levels (Table 4). Anti-
dsDNA antibody titers did not change significantly within
approximately three month of induction therapy with
CYC or MMF.While transitional B cells only increased significantly
after MMF therapy was initiated (0.8 (0.1 to 8.7) versus
3.9 (0.1 to 43.3)/μl; P = 0.0015), neither CYC nor MMF
medication affected pre- or post-switched memory B
cells significantly within 15 weeks of therapy. In contrast,
CYC, but not MMF, treatment was accompanied by a sig-
nificant decline in counts of total B lymphocytes (66.6
(13.3 to 802.2) versus 31.2 (3.0 to 206.1)/μl; P = 0.0327), of
naïve B cells (16.5 (0.0 to 481.3) versus 3.2 (0.0 to 106.4)/
μl; P = 0.0059), and of double negative (CD27−IgD−) B
cells (14.5 (2.9 to 139.6) versus 5.0 (0.7 to 38.5)/μl; P =
0.0169). Furthermore, we observed a significant increase
of circulating PDC (1.0 (0.0 to 4.3) versus 1.9 (0.2 to 6.2)/
μl; P = 0.0158) exclusively in the peripheral blood of pa-
tients undergoing treatment with CYC. Another observa-
tion only made in patients treated with CYC was a
significant increase of circulating CD8+CD44+CD62L− ef-
fector T cells (19.9 (2.2 to 157.6) versus 35.5 (4.9 to 227.8)/
μl; P = 0.0384). Neither MMF nor CYC therapy affected
other T lymphocyte subsets in the peripheral blood signifi-
cantly. Detailed information is shown in Additional files 2
Figure 2 Influence of induction therapy with mycophenolate mofetil (MMF) and cyclophosphamide (CYC) on free light chain (FLC) levels. Levels
of free kappa light chains (FLCkappa) (A) and free lambda light chains (FLClambda) (C) prior to and approximately 16 and 31 weeks after start
of induction therapy with MMF. Levels of free kappa light chains (FLCkappa) (B) and free lambda light chains (FLClambda) (D) prior to and
approximately 15 weeks after start of induction therapy with CYC. Statistical analyses were performed using the Wilcoxon’s matched pairs signed
rank test and P-values <0.05 were considered significant.
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between MMF and CYC treatment is shown in Table 4.
Correlation of free light chain levels, plasmablasts and
disease activity
In order to investigate if cellular or serological parameters
correlate with each other or with disease activity, we ana-
lyzed additional data obtained by monitoring treatment of
our lupus cohort. The results of Spearman’s rank correl-
ation test performed with data obtained from 186 patients
are shown in Table 5. The disease activity (SLEDAI-2k)
correlated significantly with HLADRhighCD27++CD38++
plasmablast counts and free light chain levels but not
with IgG levels. In addition, HLADRhighCD27++CD38++
plasmablast counts correlated significantly with levels of
free light chains.
Discussion
The results of the current study indicate a predominant
influence of MMF and CYC on B cell subsets. In addition,
CYC had an impact on numbers of circulating PDC and
CD8+CD44+CD62L− effector T cells, whereas other T cell
subsets were neither affected significantly by treatmentwith MMF nor by CYC therapy. During the early phase of
induction therapy MMF leads to a fast reduction of plas-
mablasts and plasma cells, whereas CYC has no significant
influence on these B cell subsets. The latter has also been
observed in mice suggesting a resistance of plasma cells to
CYC [21]. Circulating plasmablasts correlated significantly
with free light chains in our lupus cohort. Consistent with
these findings, free light chains as a surrogate marker for
plasma cell activation were only influenced significantly by
treatment with MMF but not with CYC. A significant re-
duction of free light chain concentrations over time is a
phenomenon also observed in patients treated with the B
cell depleting antibody rituximab [22]. In SLE patients
treated with MMF it is probably the consequence of a pre-
dominant and fast inhibiting influence of mycophenolic
acid on the synthesis of plasmablasts [16,17]. The fast
turnover of free light chains with a plasma half-life period
of two to four hours for FLCkappa and three to six hours
for FLClambda [23] compared to the long plasma half-life
period of about 21, 10 and 6 days for IgG, IgM and IgA,
respectively [24] predestines them to be used as a marker
of disease activity and early response to therapy [25,26]. In
addition, plasmablasts and free light chains might also
Table 4 Direct comparison of MMF and CYC associated changes of cellular and serological parameters during
induction therapy
Cellular and serological parameters MMF number CYC number Mann–Whitney-test
anti-dsDNA (U/ml) −2 (−5134 to +57) 21 −6 (−2135 to +1004) 18
C3c (g/L) +0.1 (−0.1 to +0.4) 23 +0.3 (−0.1 to +0.8) 24 P = 0.0036
FLCkappa (mg/L) −9.8 (−38.5 to +21.9) 20 −13.3 (−135.7 to +95.0) 23
FLClambda (mg/L) −10.5 (−41.2 to +22.3) 20 −4.1 (−76.8 to +40.0) 23
IgG (g/L) −0.3 (−3.5 to +4.8) 21 −1.3 (−27.5 to +9.1) 23
IgA (g/L) −0.3 (−4.2 to +0.9) 15 +0.1 (−1.1 to +3.7) 23 P = 0.0127
IgM (g/L) −0.3 (−0.7 to +1.5) 15 −0.1 (−1.1 to +0.8) 23
lymphocytes (/μl) −10 (−500 to +599) 23 −5 (−2040 to +1070) 24
leukocytes (/μl) +70 (−6718 to +4000) 23 +460 (−5220 to +10408) 24
platelets (× 103/μl) +30 (−116 to +202) 23 0 (−160 to +202) 24
CD19+ B lymphocytes (/μl) −2.0 (−146.6 to +110.5) 23 −7.1 (−760.6 to +165.4) 23 P = 0.0400
-CD27++CD38++ (/μl) −4.1 (−26.7 to +3.4) 23 −0.4 (−51.2 to +89.1) 23 P = 0.0014
-HLADRhighCD27++CD38++ (/μl) −2.7 (−22.9 to +2.8) 23 −0.3 (−36.2 to +57.7) 23 P = 0.0210
-HLADRlowCD27++CD38++ (/μl) −1.1 (−4.1 -to + 0.6) 23 0.0 (−14.9 to +31.4) 23 P = 0.0007
-CD27+IgD− (/μl) −0.3 (−35.2 to +13.1) 22 −2.1 (−123.0 to +49.5) 23
-CD27+IgD+ (/μl) 0.0 (−8.3 to +1.4) 22 −0.2 (−11.9 to +3.8) 23
-CD27−IgD+CD38+ (/μl) −0.1 (−79.9 to +97.2) 22 −6.5 (−475.7 to +106.4) 23 P = 0.0025
-CD27−IgD− (/μl) +0.7 (−26.3 to +17.2) 22 −2.7 (−132.2 to +22.1) 23 P = 0.0098
-CD27−IgD+CD38++ (/μl) +2.5 (−4.8 to +41.6) 23 −0.5 (−61.2 to +63.1) 23 P = 0.0107
CD3+ T lymphocytes (/μl) −14.0 (−466.0 to +363.6) 22 −27.6 (−1360.0 to +813.4) 23
CD4+ (/μl) −6.4 (−286.6 to +155.5) 22 −91.2 (−1228.0 to +593.4) 23
-CD44+CD62L− (/μl) −1.7 (−83.3 to +24.9) 22 −1.0 (−111.2 -to +175.2) 23
-CD45RA−CD45RO+ (/μl) +3.3 (−190.6 to +121.4) 22 −16.2 (−492.8 to +377.7) 23
-CD45RA+CD45RO− (/μl) +10.7 (−220.2 to +53.6) 22 −54.0 (−985.5 to +365.2) 23
CD8+ (/μl) +8.6 (−262.7 to +264.6) 22 +5.9 (−272.5 to +197.4) 23
-CD44+CD62L− (/μl) −3.1 (−205.6 to +168.8) 22 +8.3 (−106.2 to +149.3) 23
-CD45RA−CD45RO+ (/μl) −1.1 (−216.1 to +160.1) 22 +5.9 (−180.4 -to + 136.8) 23
-CD45RA+CD45RO− (/μl) +10.5 (−146.3 to +103.5) 22 +8.2 (−107.9 to +175.0) 23
CD4−CD8− (/μl) +1.2 (−32.5 ro +63.3) 22 +3.0 (−39.3 to +60.6) 23
-CD44+CD62L− (/μl) +0.5 (−13.7 to +22.0) 22 +3.0 (−9.8 to +23.5) 23
-CD45RA−CD45RO+ (/μl) +0.5 (−14.6 to +30.2) 22 +1.4 (−13.8 to +36.0) 23
-CD45RA+CD45RO− (/μl) +0.6 (−12.4 to +32.4) 22 +1.4 (−34.2 to +22.4) 23
CD123+CD11c−HLA-DRhigh PDCs (/μl) +0.6 (−4.3 to +6.3) 21 +1.2 (−3.6 to +5.6) 21
Median values and range are shown. C3c: complement factor C3c; CD4+ T cells; CD4−CD8−: double negative T cells; CD8+ T cells; CD27++CD38++: plasmablasts and
plasma cells; CD27+IgD+: pre-switched memory B cells; CD27+IgD−: post-switched memory B cells; CD27−IgD+CD38+: naïve B cells; CD27−IgD+CD38++: transitional B
cells; CD27−IgD−: double negative B cells; CD44+CD62L−: effector T cells; CD45RA+CD45RO−: naïve T cells; CD45RA−CD45RO+: memory T cells; CD123+CD11c−HLA-
DRhighPDCs: plasmacytoid dendritic cells; CYC: cyclophosphamide; FLC: free light chains; HLADRhighCD27++CD38++: plasmablasts; HLADRlowCD27++CD38++: plasma
cells; Ig: immunoglobulin; MMF: mycophenolate mofetil.
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be investigated in longitudinal studies enrolling patients
with stable disease. In this context, Hopper et al. reported
a considerable time period between the onset of light
chain secretion into the urine and the occurrence of in-
flammation [27].
Plasmablasts as well as lambda and kappa light chains
correlated significantly with the SLEDAI-2k in our lupuscohort, whereas no correlation was observed between
SLEDAI-2k and serum levels of IgG, IgM and IgA. An
association of disease activity and free light chains has
already been described in patients with SLE [22,28] or
other autoimmune disorders, such as rheumatoid arthritis
or Sjögren’s syndrome [26]. Thus, monitoring of plasma-
blasts and free light chains might be an effective tool to
predict response to treatment or flares.
Table 5 Results of a correlation analysis including cellular and serological parameters as well as SLEDAI-2k
SLEDAI-2k HLADRhighCD27++CD38++ (/μl) FLCkappa FLClambda IgG IgA
HLADRhighCD27++CD38++ (/μl) p 0.0350
rs 0.1547
FLCkappa p 0.0004 0.0002
rs 0.2591 0.2760
FLClambda p 0.0002 0.0003 <0.0001
rs 0.2726 0.2655 0.8479
IgG p ns 0.0002 <0.0001 <0.0001
rs 0.2703 0.5105 0.4328
IgA p ns <0.0001 < 0.0001 < 0.0001 < 0.0001
rs 0.3306 0.3536 0.3950 0.3027
IgM p ns ns 0.0423 0.0117 ns ns
rs 0.1528 0.1890
Data from 186 patients with SLE are shown. Results were determined by nonparametric Spearman correlation; FLC: free light chains; Ig: immunoglobulin;
HLADRhighCD27++CD38++: plasmablasts; SLEDAI-2 k: SLE disease activity index; SLE, systemic lupus erythematosus.
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longer periods of time, CYC does finally also affect plas-
mablast counts [8]. Considering the additional data ob-
tained by the current study this seems to be an indirect
and rather slow process probably related to an impact
on other cells than memory B cells or plasmablasts.
The opposite influence of MMF and CYC on IgA
levels might suggest a distinct mechanism of action of
both drugs on different subsets of antibody-forming cells,
or might simply be a consequence of a higher turnover
rate of IgA+ plasmablasts in patients with SLE. Both IgG
and IgA can activate Fc-receptors, and autoantibodies of
both isotypes seem to be associated with active disease in
SLE or antiphospholipid syndrome [29-32]. IgA secreting
plasmablasts make up 44% to 86% of all circulating anti-
body forming cells in patients with SLE [33], and it has re-
cently been reported that T2 B cells from patients with
SLE are unable to reach the gut associated lymphoid tissue
(GALT) which lacks IgA secreting cells in SLE. This was
suggested to abrogate an important checkpoint of B cell
tolerance in SLE [34]. MMF is apparently able to inhibit
plasmablast generation directly and quickly and regardless
of the character and origin of the plasmablasts. In con-
trast, CYC influences it comparatively slowly by diminish-
ing precursor cells, such as naïve or transitional B cells.
Although SLE is a disease of enhanced antibody pro-
duction and is often associated with hypergammaglobu-
linemia [35], we noticed patients with low Ig levels in
both treatment groups as well as in the control group
not receiving CYC or MMF. In contrast to prior findings
that MMF [36], but not CYC, therapy [37] is associated
with severe hypogammaglobulinemia, we observed a sig-
nificant decline of IgG and IgM after CYC, but only of
IgM after MMF was initiated. The decrease of Ig levelsafter CYC treatment has also been described in patients with
anti-neutrophil cytoplasmic antibody (ANCA)- associated
vasculitis [38]. The lack of immunoglobulins might be ex-
plained by the high proportion of proteinuric patients, as
hypogammaglobulinemia is a common finding in patients
with nephrotic syndrome [39]. In addition, patients re-
ceiving CYC or MMF for induction therapy were treated
with a relatively high dose of corticosteroids causing
lower IgG levels as well [40]. Altogether, our data suggest
that especially patients with proteinuria should be moni-
tored closely with regard to Ig levels and infections no
matter if treated with MMF or CYC. Especially a combin-
ation with other immunosuppressive agents, such as ata-
cicept [41] or ocrelizumab [42], has been described to be
associated with a higher risk for development of severe
immunoglobulin deficiency and infections.
Although lymphopenia and alterations of B cell sub-
sets have already been described in SLE [9,10,43], this
manuscript contributes to a better understanding of the
influence of the two most important immunosuppres-
sants used for induction therapy in patients with organ-
threatening disease. Induction therapy with CYC was
associated with a preferential depletion of naïve, double
negative (CD27−IgD−) and pre-switched memory B cells,
whereas treatment with MMF was not accompanied by
a depletion of transitional or naïve B cells. Hence, espe-
cially naïve B cells seem to be more susceptible to CYC, a
phenomenon also seen in patients with ANCA associated
vasculitis receiving CYC for induction therapy [44] and in
another SLE cohort [8]. Numbers of transitional B cells in-
creased significantly after MMF was started, while they
decreased after CYC was initiated, suggesting that MMF,
in contrast to other immunosuppressants, spares transi-
tional B cells. Post-switched memory cells were not
Fassbinder et al. Arthritis Research & Therapy  (2015) 17:92 Page 10 of 12influenced by either of these therapies significantly. This
is in line with the findings of other previous studies
[8,16] and might be related to the fact that memory cells
are resting cells or might sit in niches protecting them
from depletion [45].
In the context of induction therapy with CYC or MMF
we observed a significant increase in the levels of circulat-
ing PDC and CD8+CD44+CD62L− effector T cells only in
patients treated with CYC. There is evidence for CD8+ ef-
fector T cells accumulating in inflamed kidneys and caus-
ing glomerular injury in a mouse model of systemic lupus
[46] as well as in patients with severe lupus nephritis [47].
The frequency of circulating PDC is known to be low in
SLE patients [15]. A migration of PDC into inflamed or-
gans or tissues (that is, the kidneys of SLE patients with
active nephritis) [48,49] or cutaneous lesions [50,51] has
been discussed as an explanation of the low frequencies of
PDC observed in the peripheral blood of patients with
SLE during disease flares. Since we did not observe a sig-
nificant drop of PDC or CD8+CD44+CD62L− effector T
cells after MMF was introduced, our data suggest that
CYC treatment might be able to ameliorate tissue inflam-
mation more efficiently or more rapidly than MMF and
might lead to an earlier consecutive reappearance of PDCs
or CD8+CD44+CD62L− effector T cells in the peripheral
blood. These observations suggest that both drugs, used
in similar occasions, such as lupus nephritis, with compar-
able results act in a quite different manner. In addition,
these findings suggest that one or the other drug might be
more or less effective in certain patients depending on
individual features, such as their level of B cell activa-
tion or degree of tissue infiltration by activated T cells.
To customize therapy in patients with SLE, biomarkers
allowing the identification of the driving force of inflam-
mation in individual patients are needed. Free light
chains or plasmablasts might be used to identify candi-
dates who might profit from MMF treatment.
The current study has limitations because of its obser-
vational and retrospective character. Corticosteroids and
disease activity are known to affect circulating immune
cell subsets, as for instance DCs or lymphocytes. Besides
activity and organ involvement, treatment with cortico-
steroids has been shown to diminish levels of circulating
PDC in SLE [52]. Therefore, we compared treatment
groups with a similar median corticosteroid dose.
Focused on corticosteroid dose and disease activity as
major factors influencing lymphocyte and DC subsets in
SLE, other potential confounders, such as organ manifes-
tations, were not considered (Tables 1 and 2). In addition,
the local situation concerning the lack of approval of
MMF but not CYC for treating SLE and lupus nephritis
might explain further differences between the groups re-
ceiving MMF or CYC, as for instance a low rate of pre-
treated patients within the CYC group.Conclusions
Regardless of these limitations, our data suggest differ-
ences between MMF and CYC with regard to the mech-
anism of action. MMF, but not CYC, treatment leads to
a fast and enduring reduction of surrogate markers for B
cell activation, such as circulating plasmablasts, plasma
cells, and free light chains. The data might help to pave
the way for more customized therapies in SLE and the
impact of MMF and CYC on cellular and serological pa-
rameters should be considered when biomarker panels
for clinical trials are discussed and free light chains or
plasmablasts and plasma cells are monitored. In con-
trast, we did not observe a significant difference between
CYC and MMF in inducing low IgG levels during induc-
tion therapy over a time frame of three months.
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